Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

Summary

The main objective is to determine the feasibility of maintaining virologic suppression on standard plasma viral load by dose reduction of ATRIPLA ®.

Timeline

Start

2013-06-03

Primary completion

2014-11-14

Completion

2015-07-21

Publications

• Borjabad B, Rojas J, Inciarte A, Sempere A, Chivite I, Gonzalez-Cordon A, Mosquera MM, Torres B, Calvo J, de la Mora L, Martinez-Rebollar M, Laguno M, Foncillas A, Ambrosioni J, Alcami J, Miro JM, Blanco JL, Sanchez-Palomino S, Blanch J, de Lazzari E, Martinez E. Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study. J Antimicrob Chemother. 2026 Feb 2;81(3):dkag040. doi: 10.1093/jac/dkag040.
• Guardo AC, Zarama A, Gonzalez T, Bargallo ME, Rojas J, Martinez E, Plana M, Sanchez-Palomino S. Effects on immune system and viral reservoir of a short-cycle antiretroviral therapy in virologically suppressed HIV-positive patients. AIDS. 2019 May 1;33(6):965-972. doi: 10.1097/QAD.0000000000002169.
• Rojas J, Blanco JL, Sanchez-Palomino S, Marcos MA, Guardo AC, Gonzalez-Cordon A, Lonca M, Tricas A, Rodriguez A, Romero A, Miro JM, Mallolas J, Gatell JM, Plana M, Martinez E. A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity. AIDS. 2018 Jul 31;32(12):1633-1641. doi: 10.1097/QAD.0000000000001843.

Drugs

Indications